Spondyloarthritis

The effectiveness of TNF inhibitors for axial spondyloarthritis varies significantly between men and women based on BASDAI score, but not ASDAS, according to data published in Arthritis Research & Therapy.

DESTIN, Fla. — New data on discontinuation or dose reduction of biologic therapies has led to a shifting landscape in axial spondyloarthritis management, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Ultrasound can differentiate spondyloarthritis-related enthesitis from other entheseal pathologies such as mechanical enthesitis, according to data published in Annals of the Rheumatic Diseases.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

Men with inflammatory joint diseases have more children and are less likely to be childless, compared with those without inflammatory joint diseases, according to data published in the Annals of the Rheumatic Diseases.

SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.

SAN DIEGO — Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to data presented at ACR Convergence 2023.

Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.

Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.